Report top-line data from the Phase II INSPIRE study

Delivered after the deadline

AI-assessed · human review in progress Found and assessed by AI from the cited sources. Shown with its evidence; it is not counted in any Kept Score until confirmed.

Announced: 11 Mar 2021
Due: 30 Sep 2021
Delivered: March 2022

Deadline
Met
Late
Not met
Today

What the company said

“Phase II INSPIRE Top-Line Data Expected in Third Quarter”

SourceCapricor Therapeutics, Inc. Form 8-K press release, 2021-03-11
FilingSEC filing index
Deadline as statedin Third Quarter
Deadline used30 Sep 2021, the last day of the stated period
TypeProject
Permanent referenceKI-C-2021-CAPR-025605
Cite as https://keptindex.org/c/KI-C-2021-CAPR-025605/ — this address never changes.

What we found

Evidence strength A What the grades mean

The company announced the top-line data from the Phase 2 INSPIRE clinical study in March 2022, which is within the first quarter of 2022.

A
Capricor Therapeutics, Inc. 10-Q filed 2022-05-11 Regulatory filing · published 11 May 2022 · retrieved 1 Oct 2026 · kept permanently by the SEC · fingerprint 561f1cdf8ea8
“In March 2022, we announced topline data from this study.” ✓ confirmed on the page

Checked 1 Oct 2026.

Commitment lineage

Every time the company restated this commitment. The original is never changed, and the outcome is always measured against version 1.

Deadline drift +182 days
2 versions

Version 1 · original · stated 11 Mar 2021

Deadline 30 Sep 2021 (“in Third Quarter”) · wording expected
Version 2 · stated 10 Mar 2022

Deadline 31 Mar 2022 (“by the end of the first quarter of 2022”) · wording expected

“Phase 2 INSPIRE Top-Line Data Expected by End of First Quarter of 2022”
Source for this version

Commitment DNA

The structured record of this commitment. Fields the company did not state are left blank rather than guessed.

Event type: Clinical readout
Indicative materiality: Medium rules
Action: Report
Deliverable: Phase II INSPIRE study top-line data
Language: Expected (“expects”, “plans”)
In the company’s control: Medium
Specificity: Medium

How this entry was checked

Commitment recordedThe company's words were matched word for word against the filing.
First checkAn AI model read the company's later filings and recorded the outcome with a quoted passage.

Not yet confirmed. Shown on the record, but it will not count in any score until it is confirmed. How verification works

Are you Capricor Therapeutics, Inc.? You can publish an official statement next to this entry, free. Add a statement.

Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.